CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-04 | Conway Vikki L See "Remarks" | Option exercise 10b5-1 | +7,117 | 13,734 | ||
| 2024-03-04 | Conway Vikki L See "Remarks" | Sale 10b5-1 | −2,042 | $13.37 | $27K | 11,692 |
| 2024-03-04 | Conway Vikki L See "Remarks" | Option exercise · Restricted Share Units 10b5-1 | −7,117 | 14,237 | ||
| 2024-03-04 | Conway Vikki L See "Remarks" | Grant or award · Restricted Share Units 10b5-1 | +33,482 | 33,482 | ||
| 2024-03-04 | Fox Christine EVP, Head of U.S. Commercial | Grant or award · Restricted Share Units | +81,845 | 81,845 | ||
| 2024-03-04 | Grant Angus EVP, Business Development | Grant or award · Restricted Share Units | +52,083 | 52,083 | ||
| 2024-03-04 | Francis Richard D President and CEO | Sale 10b5-1 | −31,061 | $13.34 | $414K | 123,295 |
| 2024-03-04 | Francis Richard D President and CEO | Grant or award · Restricted Share Units 10b5-1 | +200,892 | 200,892 | ||
| 2024-03-04 | Drape Eric Executive VP Global Operations | Option exercise 10b5-1 | +33,512 | 77,928 | ||
| 2024-03-04 | Drape Eric Executive VP Global Operations | Option exercise · Restricted Share Units 10b5-1 | −33,512 | 67,024 | ||
| 2024-03-04 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −62,250 | $13.34 | $830K | 69,770 |
| 2024-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise 10b5-1 | +33,512 | 103,282 | ||
| 2024-03-04 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −33,512 | $13.34 | $447K | 69,770 |
| 2024-03-04 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units 10b5-1 | −33,512 | 67,024 | ||
| 2024-03-04 | Daniell Richard Exec. VP, European Commercial | Grant or award · Restricted Share Units 10b5-1 | +81,845 | 81,845 | ||
| 2024-03-04 | Hughes Eric A See "Remarks" | Sale 10b5-1 | −8,045 | $13.34 | $107K | 16,855 |
| 2024-03-04 | Hughes Eric A See "Remarks" | Grant or award · Restricted Share Units 10b5-1 | +93,005 | 93,005 | ||
| 2024-03-04 | Sabag Mark EVP, International Markets | Option exercise | +33,512 | 400,693 | ||
| 2024-03-04 | Sabag Mark EVP, International Markets | Option exercise · Restricted Share Units | −33,512 | 67,024 | ||
| 2024-03-04 | Sabag Mark EVP, International Markets | Grant or award · Restricted Share Units | +74,404 | 74,404 |
Page 23 of 76 · 1,517 trades